Startups
2010
INBIOMOTION SL (Previously SUPRAGEN SL)Developing personalized adjuvant treatment strategies for early-stage breast cancer
Unique diagnostic assay is based on a highly selective, single-gene biomarker, of the MAF gene
Unique diagnostic assay is based on a highly selective, single-gene biomarker, of the MAF gene
Address
Carrer de París 175, 08036 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2005
Institut de Recerca Biomèdica (IRB Barcelona)
CERCA Center Contact
CH
Cristina Horcajada
Institut de Recerca Biomèdica (IRB Barcelona)Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Inbiomotion focuses on providing a unique companion diagnostic solution, to address an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer.
Founded in 2010 by Prof. Roger Gomis, Inbiomotion is a spin-off of IRB Barcelona and ICREA research institutions.
Founded in 2010 by Prof. Roger Gomis, Inbiomotion is a spin-off of IRB Barcelona and ICREA research institutions.
Product description
Proprietary MAF Test: a unique companion diagnostic assay consisting of a highly adaptable in vitro diagnostic kit with automation potential
We address a massive companion diagnostics market globally, to face the steadily increasing rates of breast cancer in women worldwide
On-track to commercialize in 2022
Inbiomotion has generated two large sets of prospective-retrospective data confirming the clinical utility of the MAF Test
MAF test is technically, analytically, and clinically validated by Targos Molecular Pathology GmbH, a leading clinical research organization
Significant barrier to entry, with over 190 granted patents and patent applications
We address a massive companion diagnostics market globally, to face the steadily increasing rates of breast cancer in women worldwide
On-track to commercialize in 2022
Inbiomotion has generated two large sets of prospective-retrospective data confirming the clinical utility of the MAF Test
MAF test is technically, analytically, and clinically validated by Targos Molecular Pathology GmbH, a leading clinical research organization
Significant barrier to entry, with over 190 granted patents and patent applications